Abstract
- Cases of arterial aneurysm or dissection have been reported with VEGF inhibitors, such as bevacizumab, used to treat cancer. Systemic administration and hypertension, a known adverse effect of these anti-angiogenic drugs, are risk factors.
- In practice, monitoring is warranted for patients treated with VEGF inhibitors, especially those with cardiovascular risk factors.
©Prescrire 1 September 2020
Source: "VEGF inhibitors: arterial aneurysm and dissection" Prescrire International 2020; 29 (218): 214. Free.
Enjoy full access to Prescrire International, and support independent information
|